open access

Vol 8, No 1 (2023)
Letter to the Editor
Published online: 2023-03-21
Get Citation

Antiplatelet therapy in elderly patients after acute coronary syndrome

Salvatore Di Somma1, Robert Gajda2, Wacław Kochman3
·
Medical Research Journal 2023;8(1):87-88.
Affiliations
  1. Department of Medical-Surgery Sciences and Translational Medicine, University La Sapienza, Rome, Italy
  2. Gajda-Med Medical Centre in Pultusk, Pultusk, Poland
  3. Centre of Postgraduate Medical Education, Bielanski Hospital, Warsaw, Poland

open access

Vol 8, No 1 (2023)
LETTERS TO THE EDITOR
Published online: 2023-03-21

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Antiplatelet therapy in elderly patients after acute coronary syndrome

Journal

Medical Research Journal

Issue

Vol 8, No 1 (2023)

Article type

Letter to the Editor

Pages

87-88

Published online

2023-03-21

Page views

2107

Article views/downloads

273

DOI

10.5603/MRJ.a2023.0014

Bibliographic record

Medical Research Journal 2023;8(1):87-88.

Authors

Salvatore Di Somma
Robert Gajda
Wacław Kochman

References (29)
  1. Servi SDe, Landi A. Antiplatelet treatment for older patients with ACS — a challenging issue. Med Res J. 2023.
  2. Savonitto S, Ferri LA, Piatti L, et al. Elderly ACS 2 Investigators. A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. Am Heart J. 2016; 181(23): 101–106.
  3. Crimi G, Morici N, Ferrario M, et al. Time course of ischemic and bleeding burden in elderly patients with acute coronary syndromes randomized to low-dose prasugrel or clopidogrel. J Am Heart Assoc. 2019; 8(2): e010956.
  4. De Servi S, Landi A, Savonitto S, et al. Tailoring oral antiplatelet therapy in acute coronary syndromes: from guidelines to clinical practice. J Cardiovasc Med (Hagerstown). 2023; 24(2): 77–86.
  5. Kubica J, Adamski P, Gorog DA, et al. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiol J. 2020; 27(6): 661–676.
  6. Sibbing D, Aradi D, Jacobshagen C, et al. TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017; 390(10104): 1747–1757.
  7. Kubica J, Adamski P, Niezgoda P, et al. A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiol J. 2021; 28(4): 607–614.
  8. Kheiri B, Osman M, Abdalla A, et al. De-escalation of antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials. J Cardiovasc Pharmacol Ther. 2019; 24(2): 153–159.
  9. Kim HK, Kubica J, Jeong YH. Ticagrelor vs clopidogrel for patients with acute coronary syndrome undergoing percutaneous intervention. JAMA. 2021; 325(9): 890.
  10. Kubica J, Adamski P, Buszko K, et al. Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study. Eur Heart J Cardiovasc Pharmacother. 2018; 4(3): 152–157.
  11. Kubica J, Adamski P, Buszko K, et al. Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. Eur Heart J Cardiovasc Pharmacother. 2019; 5(3): 139–148.
  12. Adamski P, Ostrowska M, Navarese EP, et al. Pharmacodynamic and clinical efficacy of reduced ticagrelor maintenance doses in patients with coronary artery disease. Curr Med Res Opin. 2021; 37(2): 195–206.
  13. Ostrowska M, Kubica J, Adamski P, et al. Stratified approaches to antiplatelet therapies based on platelet reactivity testing. Front Cardiovasc Med. 2019; 6: 176.
  14. Pietrzykowski Ł, Kasprzak M, Michalski P, et al. Therapy discontinuation after myocardial infarction. J Clin Med. 2020; 9(12).
  15. Kubica A, Obońska K, Fabiszak T, et al. Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials. Curr Med Res Opin. 2016; 32(8): 1441–1451.
  16. Kubica A, Kasprzak M, Obońska K, et al. Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction. Pharmacology. 2015; 95(1-2): 50–58.
  17. Kubica A, Gruchała M, Jaguszewski M, et al. Adherence to treatment — a pivotal issue in long-term treatment of patients with cardiovascular diseases. An expert standpoint. Med Res J. 2018; 2(4): 123–127.
  18. Kubica A, Adamski P, Bączkowska A, et al. The rationale for multilevel educational and motivational intervention in patients after myocardial infarction (MEDMOTION) project is to support multicentre randomized clinical trial evaluating safety and efficacy of two ticagrelor-based de-escalation antiplatelet strategies in acute coronary syndrome (ELECTRA – SIRIO 2). Med Res J. 2020; 5(4): 244–249.
  19. Pietrzykowski Ł, Michalski P, Kosobucka A, et al. Medication adherence and its determinants in patients after myocardial infarction. Sci Rep. 2020; 10(1): 12028.
  20. Kosobucka A, Pietrzykowski Ł, Michalski P, et al. Impact of readiness for discharge from the hospital on the implementation of the therapeutic plan. Medl Res J. 2020; 5(4): 256–264.
  21. Buszko K, Pietrzykowski Ł, Michalski P, et al. Validation of the Functioning in Chronic Illness Scale (FCIS). Medical Research Journal. 2018; 3(2): 63–69.
  22. Pietrzykowski Ł, Michalski P, Kosobucka A, et al. Knowledge about health and disease in obese patients after myocardial infarction. An observational study. Med Res J. 2018; 2(4): 135–140.
  23. Buszko K, Kosobucka A, Michalski P, et al. The readiness for hospital discharge of patients after acute myocardial infarction: a new self-reported questionnaire. Medl Res J. 2017; 2(1): 20–28.
  24. Kubica A. Self-reported questionnaires for a comprehensive assessment of patients after acute coronary syndrome. Med Res J. 2019; 4(2): 106–109.
  25. Kosobucka A, Michalski P, Pietrzykowski Ł, et al. The impact of readiness to discharge from hospital on adherence to treatment in patients after myocardial infarction. Cardiol J. 2022; 29(4): 582–590.
  26. Kubica A, Kosobucka A, Fabiszak T, et al. Assessment of adherence to medication in patients after myocardial infarction treated with percutaneous coronary intervention. Is there a place for newself-reported questionnaires? Curr Med Res Opin. 2019; 35(2): 341–349.
  27. Kosobucka A, Michalski P, Pietrzykowski Ł, et al. Adherence to treatment assessed with the Adherence in Chronic Diseases Scale in patients after myocardial infarction. Patient Prefer Adherence. 2018; 12: 333–340.
  28. Michalski P, Kasprzak M, Siedlaczek M, et al. The impact of knowledge and effectiveness of educational intervention on readiness for hospital discharge and adherence to therapeutic recommendations in patients with acute coronary syndrome. Med Res J. 2020: 72–78.
  29. Kubica A, Kosobucka A, Michalski P, et al. Self-reported questionnaires for assessment adherence to treatment in patients with cardiovascular diseases. Med Res J. 2018; 2(4): 115–122.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl